What is the appropriate management for a 66-year-old man with low total testosterone (235 ng/dL), low free testosterone (3.8 pg/mL), mildly elevated luteinizing hormone (10.2 IU/L), normal prolactin (10.6 ng/mL) and normal prostate‑specific antigen (2.8 ng/mL)?

Management Recommendation

This patient should be offered a trial of testosterone replacement therapy if he has bothersome sexual dysfunction symptoms, with reassessment at 12 months and discontinuation if no improvement occurs 1.

Diagnostic Assessment

This 66-year-old man presents with biochemical hypogonadism:

• Total testosterone 235 ng/dL (below the 300 ng/dL threshold used in most guidelines)
• Free testosterone 3.8 pg/mL (well below the lower reference limit of 66 pg/mL for adult men) 2
• Elevated LH 10.2 IU/L indicates primary hypogonadism (testicular failure with appropriate pituitary response)
• Normal prolactin and PSA rule out pituitary pathology and do not contraindicate testosterone therapy

The elevated LH with low testosterone confirms this is primary (testicular) hypogonadism, not secondary (pituitary/hypothalamic) dysfunction 3.

Treatment Decision Algorithm

Step 1: Assess for Symptoms

Critical determination: Does the patient have bothersome sexual dysfunction (erectile dysfunction, decreased libido, reduced ejaculate volume)?

• If YES to sexual dysfunction: Proceed to Step 2
• If NO or only nonspecific symptoms (fatigue, decreased energy, cognitive complaints): Do NOT initiate testosterone therapy 1

The 2020 American College of Physicians guideline explicitly recommends against testosterone treatment for energy, vitality, physical function, or cognition, as evidence shows minimal benefit for these outcomes 1.

Step 2: Screen for Contraindications

Absolute contraindications to testosterone therapy:

• Prostate or breast cancer
• Erythrocytosis (hematocrit >50%)
• Severe untreated sleep apnea
• Uncontrolled heart failure
• Recent major cardiovascular event (<6 months)
• Desire for fertility (testosterone suppresses spermatogenesis in primary hypogonadism) 3, 4

This patient's PSA of 2.8 ng/mL is normal and does not contraindicate therapy 4.

Step 3: Address Modifiable Factors First

Before initiating testosterone:

• Evaluate and optimize metabolic conditions: Check for obesity, metabolic syndrome, diabetes 3
• Review medications that may suppress testosterone (opioids, glucocorticoids)
• Weight loss in obese men can improve testosterone levels and may obviate need for therapy 3

The 2025 European Association of Urology guidelines emphasize that functional hypogonadism associated with obesity may reverse with lifestyle modification 3.

Step 4: Initiate Therapy if Appropriate

For men with sexual dysfunction symptoms:

Formulation choice: Intramuscular testosterone is preferred over transdermal preparations due to significantly lower cost with equivalent efficacy and safety 1. Common regimens include testosterone cypionate or enanthate 100-200 mg every 1-2 weeks.

Shared decision-making discussion must include:

• Potential benefits: Improved sexual function (modest effect)
• Harms: Erythrocytosis, possible cardiovascular risks, worsening sleep apnea, testicular atrophy, infertility
• Low-certainty evidence base
• Cost and need for lifelong therapy 1

Monitoring Protocol

Initial Follow-up (3 months):

• Total testosterone level (target mid-normal range: 400-700 ng/dL)
• Hematocrit (discontinue if >54%)
• Symptom assessment
• PSA (monitor for rapid rise >1.4 ng/mL/year) 4

12-Month Reassessment (Critical):

Discontinue testosterone if no improvement in sexual function 1. This is a firm recommendation from the ACP guideline—continuation without benefit is not justified given uncertain long-term safety.

Ongoing Monitoring (if continued):

• Every 6-12 months: testosterone level, hematocrit, PSA, symptom assessment
• Annual digital rectal examination in men >50 years 4

Key Clinical Pitfalls

1. Do not treat based solely on laboratory values: Testosterone therapy requires both low testosterone AND specific symptoms (primarily sexual dysfunction) 3, 1

2. Primary hypogonadism cannot be treated with fertility-preserving options: Unlike secondary hypogonadism, this patient cannot use hCG or clomiphene to restore both testosterone and fertility 3

3. Nonspecific symptoms are poor indicators: Fatigue, low energy, and cognitive complaints have minimal response to testosterone and should not drive treatment decisions 1

4. The PSA level of 2.8 ng/mL is NOT a contraindication: However, PSA <4 ng/mL in the setting of high-grade prostate cancer can indicate low testosterone, so baseline screening is appropriate 5

5. Avoid testing during acute illness: Testosterone levels drop during acute medical conditions and do not reflect true baseline 3

Evidence Quality Note

The most recent 2025 EAU guidelines 3 provide the framework for diagnosis and emphasize lifestyle modification, while the 2020 ACP guidelines 1 provide the strongest evidence-based treatment recommendations. Both converge on the principle that testosterone therapy should be reserved for men with clear sexual dysfunction symptoms and biochemical hypogonadism, with mandatory reassessment and discontinuation if ineffective.